Filing Flows › Supernus Pharmaceuticals (SUPN) › Q3 2026 › vs Q2 2026
Supernus Pharmaceuticals (SUPN) Q3 2026 vs Q2 2026 (quarter over quarter)
Supernus Pharmaceuticals's revenue rose $7.7M (+4%) from $219M in Q2 2026 to $227M in Q3 2026. The biggest changes: Net product sales +$14.5M (+9%); Royalty, licensing, and other revenues −$11.5M (-64%); ONAPGO +$3.5M (+26%). Operating margin 9.3% against -26.5% (+35.8 pts).
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 9.3% | -26.5% | +35.8 pts |
| Net margin | 9.2% | -26.6% | +35.9 pts |
| Free cash flow margin | 2.8% | -2.5% | +5.3 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Qelbree | $90.8M | $89.2M | $1.6M | +2% |
| GOCOVRI | $42.6M | $37.5M | $5.1M | +14% |
| Collaboration revenue (ZURZUVAE) | $41.7M | $35.4M | $6.3M | +18% |
| Other | $3.4M | $1.9M | $1.5M | +79% |
| Net product sales | $179M | $164M | $14.5M | +9% |
| ONAPGO | $17.1M | $13.5M | $3.5M | +26% |
| Trokendi XR | $10.2M | $8.4M | $1.8M | +21% |
| Oxtellar XR | $8.0M | $8.8M | −$825K | -9% |
| Royalty, licensing, and other revenues | $6.5M | $18.0M | −$11.5M | -64% |
| APOKYN | $6.5M | $6.3M | $167K | +3% |
| Revenue | $227M | $219M | $7.7M | +4% |
| Other income, net | $1.5M | $315K | $1.2M | +386% |
| Operating profit | $21.2M | −$58.0M | $79.1M | — |
| Costs & expenses | $206M | $277M | −$71.4M | -26% |
| Pre-tax earnings | $22.7M | −$57.6M | $80.4M | — |
| Cost of revenue | $27.0M | $33.7M | −$6.7M | -20% |
| Research & development | $25.8M | $29.5M | −$3.7M | -13% |
| SG&A | $128M | $134M | −$5.6M | -4% |
| Other operating costs | $24.8M | $80.3M | −$55.5M | -69% |
| Net earnings | $20.9M | −$58.4M | $79.3M | — |
| Income tax | $1.8M | $723K | $1.1M | +148% |
| Operating cash sources | $53.5M | −$24.0M | $77.5M | — |
| Depreciation & amortization | $23.6M | $25.7M | −$2.1M | -8% |
| Share-based compensation | $8.9M | $8.6M | $293K | +3% |
| Working capital & other | $46.9M | −$19.2M | $66.0M | — |
| Operating cash flow | $6.6M | −$4.8M | $11.4M | — |
| Free cash flow (OCF − capex) | $6.4M | −$5.4M | $11.8M | — |
| Capital expenditures | $230K | $568K | −$338K | -60% |
Questions
How much did Supernus Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Supernus Pharmaceuticals's revenue rose $7.7M (+4%) from $219M in Q2 2026 to $227M in Q3 2026.
What drove Supernus Pharmaceuticals's revenue change in Q3 2026?
Net product sales +$14.5M (+9%); Royalty, licensing, and other revenues −$11.5M (-64%); ONAPGO +$3.5M (+26%).